Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q1 2026

InMed Pharmaceuticals Q1 2026 Results: Net Loss of $2.33M, Loss Widens

InMed Pharmaceuticals Inc. reported its financial results for the quarter ended September 30, 2026, highlighting ongoing research and development expenses related to its cannabinoid-based pipeline. The company continues to manage its cash position to fund clinical trials and proprietary manufacturing technology development.

Q1 2026 at a glance · $ million
MetricQ1 2026Q1 2025
Profit before tax-2.0-1.8
Net income-2.3-1.7
EPS (diluted, $ a share)$-0.42$-0.44

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: MTRI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

InMed Pharmaceuticals Inc.: key numbers

Share price
$17.50Close, Nov 17
Market cap
$96.1M
Shares outstanding
5.49MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from InMed Pharmaceuticals Inc.

All →
7:03 AM ET 8-K
M&A Deal

InMed Pharmaceuticals M&A Deal with Mentari Therapeutics, Inc.

InMed Pharmaceuticals Inc. (now renamed Mentari Therapeutics, Inc.) completed its previously announced business combination with private Delaware corporation Mentari Therapeutics on November 6, 2026. This filing provides the required historical financial statements and management's discussion for the acquired Mentari entity for the period ended September 30, 2026. The combined company now trades on Nasdaq under the ticker 'MTRI'.

Counterparty
Mentari Therapeutics, Inc.
4:46 PM ET 8-K
M&A Deal

InMed Pharmaceuticals Signs $490M M&A Deal with Mentari Therapeutics, Inc.

InMed Pharmaceuticals Inc. (renamed Mentari Therapeutics, Inc.) completed its business combination with private Delaware corporation Mentari Therapeutics, Inc. on November 6, 2026. The transaction included a pre-closing financing that raised $490 million in aggregate gross proceeds. The combined company will focus on developing therapies for migraine prevention and is led by the Mentari management team.

Value
$490M
Counterparty
Mentari Therapeutics, Inc.
8:18 PM ET Form 4
Insider Buying

InMed Pharmaceuticals Insider ADAR1 Capital Management LLC Buys $34.6K of Stock

ADAR1 Capital Management LLC bought 2,640 shares of InMed Pharmaceuticals Inc. at $13.10 a share, worth $34.6K in total on Nov 5, 2026. Shares held after the trade: 98,297 (+2.8%).

Value
$34.6K
Shares
2,640
Price
$13.10
Holding change
+2.8%
Trade date
Nov 5, 2026
8:05 AM ET 8-K
M&A Deal

InMed Pharmaceuticals Signs $490M M&A Deal with InMed Pharmaceuticals Inc.

Mentari Therapeutics completed its merger with InMed Pharmaceuticals Inc. and began trading on Nasdaq under the ticker 'MTRI'. In connection with the closing, the company completed $490 million in private placement financings to fund its pipeline of migraine prevention biologics, including MT-001 and MT-002.

Value
$490M
Counterparty
InMed Pharmaceuticals Inc.
8:08 AM ET 8-K
Reverse Stock Split

InMed Pharmaceuticals Reverse Stock Split

InMed Pharmaceuticals completed a 1-for-10 reverse stock split (consolidation), reducing its outstanding shares from approximately 5.49 million to 549,374. The company also legally changed its name to Mentari Therapeutics, Inc. and confirmed shareholder approval of all matters at its 2026 Annual General and Special Meeting.

6:06 AM ET 8-K
Reverse Stock Split

InMed Pharmaceuticals Reverse Stock Split

InMed Pharmaceuticals Inc. (renamed Mentari Therapeutics, Inc.) completed a 1-for-10 reverse stock split (consolidation) of its common shares effective November 4, 2026. The split reduced the outstanding share count from approximately 5.49 million to 0.55 million shares to facilitate its pending merger and reorganization with Mentari Therapeutics, Inc. (Delaware).

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.